Denver PWM’s BioMarin Pharmaceuticals BMRN Stock Holding History

Denver PWM’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-785	Closed	-$51.8K	–	86
2019 Q3	$51.8K	Buy	+785	New	+$60.5K	0.03%	123

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Denver PWM's BMRN Position: Q4 2019 in Review

Denver PWM sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 785 shares — an estimated $51.8K sold.

Denver PWM first reported a position in BMRN in Q3 2019 and held it in 1 quarter. The position peaked at $51.8K in Q3 2019. 467 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

Denver PWM reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Denver PWM sold 785 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $51.8K.
Denver PWM first reported a position in BioMarin Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Denver PWM's BioMarin Pharmaceuticals position peaked at $51.8K in Q3 2019.
467 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on Denver PWM's 13F filing for Q4 2019, filed 8 Jan 2020.